LY22-02e

Efficacy and safety of CD19 directed CAR T-cell therapy for primary mediastinal B-cell lymphoma.

Study #: LY22-02e

Study Status: Published

Presentation(s)

2025, Tandem (Poster)

CD19 CAR T-cell therapy for primary mediastinal large B-cell lymphoma: a CIBMTR analysis.

Citation

Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, Delgado J, Grover N, Haverkos B, de Lima M, Malone A, Mussetti A, Nieto Y, Pawarode A, Pearson L, Solh M, Sureda A, Tun AM, Wudhikran K, Yamshon S, Shadman M, Turtle CJ, Hamadani M, Herrera AF.

American Journal of Hematology. 2025, Sep 28: 100(10): 100(10):17. doi: 10.1002/ajh.70033. Epub 2025, Aug 11. PMCID:PMC12608806.

PubMed

PMID: 40785644

Abstract